94 related articles for article (PubMed ID: 1838982)
1. Antioxidants prevent the interaction of 3,4-dihydroxyphenylacetic acid at the dopamine D2 receptor.
Cammack J; Tessel R; Michaelis E; Adams RN
Eur J Pharmacol; 1991 Aug; 201(1):111-3. PubMed ID: 1838982
[TBL] [Abstract][Full Text] [Related]
2. Relation between brain dopamine loss and D2 dopamine receptor density in MPTP monkeys.
Falardeau P; Bédard PJ; Di Paolo T
Neurosci Lett; 1988 Mar; 86(2):225-9. PubMed ID: 2966905
[TBL] [Abstract][Full Text] [Related]
3. Endurance training effects on striatal D2 dopamine receptor binding and striatal dopamine metabolite levels.
MacRae PG; Spirduso WW; Cartee GD; Farrar RP; Wilcox RE
Neurosci Lett; 1987 Aug; 79(1-2):138-44. PubMed ID: 2959886
[TBL] [Abstract][Full Text] [Related]
4. Ascorbic acid, redox cycling, lipid peroxidation, and the binding of dopamine receptor antagonists.
Heikkila RE; Manzino L
Ann N Y Acad Sci; 1987; 498():63-76. PubMed ID: 3476003
[No Abstract] [Full Text] [Related]
5. Ascorbic acid reduces accumulation of [3H]spiperone in mouse striatum in vivo.
Dorris RL
Proc Soc Exp Biol Med; 1987 Oct; 186(1):13-6. PubMed ID: 3628250
[TBL] [Abstract][Full Text] [Related]
6. [Relation between brain D2-dopamine receptors and 3H-spiperone binding sites of intact lymphocytes].
Noguchi-kuno SA; Nakata C; Nishitani H
Rinsho Shinkeigaku; 1983 Sep; 23(9):814-8. PubMed ID: 6232031
[No Abstract] [Full Text] [Related]
7. Effects of a fluorinated pyrimidinedione anti-cancer drug, 5-fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione (FT), and related compounds on nigro-striatal dopaminergic neurons in the central nervous system.
Toide K; Unemi N; Segawa T
Arch Int Pharmacodyn Ther; 1985 Mar; 274(1):111-24. PubMed ID: 3925907
[TBL] [Abstract][Full Text] [Related]
8. Interaction of flunarizine with dopamine D2 and D1 receptors.
Ambrosio C; Stefanini E
Eur J Pharmacol; 1991 May; 197(2-3):221-3. PubMed ID: 1833208
[TBL] [Abstract][Full Text] [Related]
9. Dopamine receptor affinities in vitro and neurochemical effects in vivo of pergolide and its metabolites.
Wong DT; Threlkeld PG; Bymaster FP
Arzneimittelforschung; 1993 Apr; 43(4):409-12. PubMed ID: 7684223
[TBL] [Abstract][Full Text] [Related]
10. Dopamine receptor plasticity following MPTP-induced nigrostriatal lesions in the mouse.
Weihmuller FB; Bruno JP; Neff NH; Hadjiconstantinou M
Eur J Pharmacol; 1990 May; 180(2-3):369-72. PubMed ID: 2365010
[TBL] [Abstract][Full Text] [Related]
11. Effects of heavy metal cations, sulfhydryl reagents and other chemical agents on striatal D2 dopamine receptors.
Scheuhammer AM; Cherian MG
Biochem Pharmacol; 1985 Oct; 34(19):3405-13. PubMed ID: 3931643
[TBL] [Abstract][Full Text] [Related]
12. Aging process affects a single class of dopamine receptors.
Memo M; Lucchi L; Spano PF; Trabucchi M
Brain Res; 1980 Dec; 202(2):488-92. PubMed ID: 7437912
[TBL] [Abstract][Full Text] [Related]
13. In vivo [3H]spiperone binding: evidence for accumulation in corpus striatum by agonist-mediated receptor internalization.
Chugani DC; Ackermann RF; Phelps ME
J Cereb Blood Flow Metab; 1988 Jun; 8(3):291-303. PubMed ID: 2966803
[TBL] [Abstract][Full Text] [Related]
14. Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain.
Wilmot CA; Szczepanik AM
Brain Res; 1989 May; 487(2):288-98. PubMed ID: 2525063
[TBL] [Abstract][Full Text] [Related]
15. Early administration of tiapride to young rats without long-lasting changes in the development of the dopaminergic system.
Bock N; Moll GH; Wicker M; Pilz J; Rüther E; Banaschewski T; Huether G; Rothenberger A
Pharmacopsychiatry; 2004 Jul; 37(4):163-7. PubMed ID: 15467972
[TBL] [Abstract][Full Text] [Related]
16. Differentiation by ascorbic acid of dopamine agonist and antagonist binding sites in striatum.
Kayaalp SO; Neff NH
Life Sci; 1980 Jun; 26(22):1837-41. PubMed ID: 7401904
[No Abstract] [Full Text] [Related]
17. [3H]spiperone binds selectively to rat striatal D2 dopamine receptors in vivo: a kinetic and pharmacological analysis.
Leslie CA; Bennett JP
Brain Res; 1987 Mar; 407(2):253-62. PubMed ID: 2952221
[TBL] [Abstract][Full Text] [Related]
18. Chemical modification reveals involvement of tyrosine in ligand binding to dopamine D1 and D2 receptors.
Srivastava LK; Mishra RK
Biochem Int; 1990; 21(4):705-14. PubMed ID: 2241996
[TBL] [Abstract][Full Text] [Related]
19. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
Hancock AA; Marsh CL
Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
[TBL] [Abstract][Full Text] [Related]
20. Modulation of activity of the striatal dopaminergic system during the hibernation cycle.
Kilduff TS; Bowersox SS; Faull KF; Zeller-DeAmicis L; Radeke CM; Ciaranello RD; Heller HC; Barchas JD; Dement WC
J Neurosci; 1987 Sep; 7(9):2732-6. PubMed ID: 3625271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
